WEKO3
アイテム
{"_buckets": {"deposit": "4a698d88-3784-4013-8e1b-0d413ed63197"}, "_deposit": {"created_by": 2, "id": "1273", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1273"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001273", "sets": ["9"]}, "author_link": ["5902", "5903", "5907", "5906", "5908", "5910", "5905", "5904", "5909"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "3273", "bibliographicPageStart": "3267", "bibliographicVolumeNumber": "16", "bibliographic_titles": [{"bibliographic_title": "Oncology Letters"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Exosomal microRNAs (miRNAs) have been investigated as potential novel biomarkers, and miR-122 and miR-21 were shown to be important in hepatocellular carcinoma (HCC). We analyzed the importance of serum exosomal miRNA expression levels in HCC patients that underwent transarterial chemoembolization (TACE). Seventy-five HCC patients who underwent TACE as the initial treatment in Nagasaki University Hospital were enrolled. Exosomal miRNAs were isolated from serum samples collected before and after TACE. Exosomal miR-122 expression levels significantly decreased after TACE (P=0.012), while the exosomal miR-21 expression levels did not significantly change. The expression levels of exosomal miR-122 before TACE were shown to correlate significantly with aspartate aminotransferase (r=0.31, P=0.004) and alanine aminotransferase (r=0.33, P=0.003) levels, tumor diameter (r=0.29, P=0.010) and Child-Pugh score (r=-0.28, P=0.013). The median survival time for all patients was 47 months, and neither of the investigated exosomal miRNAs were shown to be independent factors associated with the disease-specific survival. According to the median relative expression of miR-122 after TACE/before TACE (miR-122 ratio) in liver cirrhosis patients (n=57), the patients with a higher miR-122 ratio had significantly longer disease-specific survival, compared with that of the patients with the lower miR-122 ratio (P=0.0461). Multivariate Cox proportional hazards regression analysis of clinical parameters revealed that a lower exosomal miR-122 ratio (HR 2.720; 95% confidence interval, 1.035-8.022; P=0.042) is associated with the disease-specific survival. Taken together, our results demonstrate that the exosomal miR-122 level alterations may represent a predictive biomarker in HCC patients with liver cirrhosis treated with TACE.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Oncology Letters, 16(3), pp.3267-3273; 2018 ", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Spandidos Publications"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3892/ol.2018.8991", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2018, Spandidos Publications. All rights reserved."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "17921074", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "17921082", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Suehiro, Tomoyuki"}], "nameIdentifiers": [{"nameIdentifier": "5902", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyaaki, Hisamitsu"}], "nameIdentifiers": [{"nameIdentifier": "5903", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanda, Yasuko"}], "nameIdentifiers": [{"nameIdentifier": "5904", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibata, Hidetaka"}], "nameIdentifiers": [{"nameIdentifier": "5905", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Honda, Takuya"}], "nameIdentifiers": [{"nameIdentifier": "5906", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ozawa, Eisuke"}], "nameIdentifiers": [{"nameIdentifier": "5907", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miuma, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "5908", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taura, Naota"}], "nameIdentifiers": [{"nameIdentifier": "5909", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "5910", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "OncLet16_3267.pdf", "filesize": [{"value": "831.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 831900.0, "url": {"label": "OncLet16_3267.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1273/files/OncLet16_3267.pdf"}, "version_id": "4c58900e-261a-4c85-b931-2286a07b48c1"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Carcinoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Chemoembolization, Exosome", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hepatocellular", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MicroRNA", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Therapeutic", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Serum exosomal microRNA?122 and microRNA?21 as predictive biomarkers in transarterial chemoembolization?treated hepatocellular carcinoma patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Serum exosomal microRNA?122 and microRNA?21 as predictive biomarkers in transarterial chemoembolization?treated hepatocellular carcinoma patients"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/38531", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-04-01"}, "publish_date": "2019-04-01", "publish_status": "0", "recid": "1273", "relation": {}, "relation_version_is_last": true, "title": ["Serum exosomal microRNA?122 and microRNA?21 as predictive biomarkers in transarterial chemoembolization?treated hepatocellular carcinoma patients"], "weko_shared_id": -1}
Serum exosomal microRNA?122 and microRNA?21 as predictive biomarkers in transarterial chemoembolization?treated hepatocellular carcinoma patients
http://hdl.handle.net/10069/38531
http://hdl.handle.net/10069/38531a10847bf-5101-4b83-b17c-75fdb11ef06a
名前 / ファイル | ライセンス | アクション |
---|---|---|
OncLet16_3267.pdf (831.9 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-04-01 | |||||
タイトル | ||||||
タイトル | Serum exosomal microRNA?122 and microRNA?21 as predictive biomarkers in transarterial chemoembolization?treated hepatocellular carcinoma patients | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Carcinoma | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chemoembolization, Exosome | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hepatocellular | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MicroRNA | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Therapeutic | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Suehiro, Tomoyuki
× Suehiro, Tomoyuki× Miyaaki, Hisamitsu× Kanda, Yasuko× Shibata, Hidetaka× Honda, Takuya× Ozawa, Eisuke× Miuma, Satoshi× Taura, Naota× Nakao, Kazuhiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Exosomal microRNAs (miRNAs) have been investigated as potential novel biomarkers, and miR-122 and miR-21 were shown to be important in hepatocellular carcinoma (HCC). We analyzed the importance of serum exosomal miRNA expression levels in HCC patients that underwent transarterial chemoembolization (TACE). Seventy-five HCC patients who underwent TACE as the initial treatment in Nagasaki University Hospital were enrolled. Exosomal miRNAs were isolated from serum samples collected before and after TACE. Exosomal miR-122 expression levels significantly decreased after TACE (P=0.012), while the exosomal miR-21 expression levels did not significantly change. The expression levels of exosomal miR-122 before TACE were shown to correlate significantly with aspartate aminotransferase (r=0.31, P=0.004) and alanine aminotransferase (r=0.33, P=0.003) levels, tumor diameter (r=0.29, P=0.010) and Child-Pugh score (r=-0.28, P=0.013). The median survival time for all patients was 47 months, and neither of the investigated exosomal miRNAs were shown to be independent factors associated with the disease-specific survival. According to the median relative expression of miR-122 after TACE/before TACE (miR-122 ratio) in liver cirrhosis patients (n=57), the patients with a higher miR-122 ratio had significantly longer disease-specific survival, compared with that of the patients with the lower miR-122 ratio (P=0.0461). Multivariate Cox proportional hazards regression analysis of clinical parameters revealed that a lower exosomal miR-122 ratio (HR 2.720; 95% confidence interval, 1.035-8.022; P=0.042) is associated with the disease-specific survival. Taken together, our results demonstrate that the exosomal miR-122 level alterations may represent a predictive biomarker in HCC patients with liver cirrhosis treated with TACE. | |||||
書誌情報 |
Oncology Letters 巻 16, 号 3, p. 3267-3273, 発行日 2018-09 |
|||||
出版者 | ||||||
出版者 | Spandidos Publications | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 17921074 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 17921082 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3892/ol.2018.8991 | |||||
権利 | ||||||
権利情報 | c 2018, Spandidos Publications. All rights reserved. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Oncology Letters, 16(3), pp.3267-3273; 2018 |